مکتبة رقمیه للعلوم الطبيه
Your cart is empty.
  • Cart
  • Lists
    Your lists Log in to create your own lists
  • Log in to your account
  • Your cookies
  • Search history
  • Advanced search
  • Authority search
  • Tag cloud
  • Library

Log in to your account

  1. Home
  2. Details for: Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Normal view MARC view ISBD view

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. [electronic resource]

By:
  • Sharma, Shruti
Contributor(s):
  • Galanina, Natalie
  • Guo, Ailin
  • Lee, Jimmy
  • Kadri, Sabah
  • Van Slambrouck, Charles
  • Long, Bradley
  • Wang, Weige
  • Ming, Mei
  • Furtado, Larissa V
  • Segal, Jeremy P
  • Stock, Wendy
  • Venkataraman, Girish
  • Tang, Wei-Jen
  • Lu, Pin
  • Wang, Yue Lynn
Producer: 20180322Description: 68833-68841 p. digitalISSN:
  • 1949-2553
Subject(s):
  • Adenine -- analogs & derivatives
  • Agammaglobulinaemia Tyrosine Kinase
  • Antineoplastic Agents -- therapeutic use
  • Cell Transformation, Neoplastic
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm
  • Female
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
  • Middle Aged
  • Mutation
  • Neoplasm Recurrence, Local
  • Piperidines
  • Protein Kinase Inhibitors -- therapeutic use
  • Protein-Tyrosine Kinases -- genetics
  • Pyrazoles -- therapeutic use
  • Pyrimidines -- therapeutic use
  • src Homology Domains
Online resources:
  • Available from publisher's website
In: Oncotarget vol. 7
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Cancel rating. Average rating: 0.0 (0 votes)
  • Holdings ( 0 )
  • Title notes ( 1 )
  • Comments ( 0 )
No physical items for this record

Publication Type: Case Reports; Journal Article

There are no comments on this title.

Log in to your account to post a comment.

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.

APA

Sharma S., Galanina N., Guo A., Lee J., Kadri S., Van Slambrouck C., Long B., Wang W., Ming M., Furtado L. V., Segal J. P., Stock W., Venkataraman G., Tang W., Lu P. & Wang Y. L. (20180322). Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. : Oncotarget.

Chicago

Sharma Shruti, Galanina Natalie, Guo Ailin, Lee Jimmy, Kadri Sabah, Van Slambrouck Charles, Long Bradley, Wang Weige, Ming Mei, Furtado Larissa V, Segal Jeremy P, Stock Wendy, Venkataraman Girish, Tang Wei-Jen, Lu Pin and Wang Yue Lynn. 20180322. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. : Oncotarget.

Harvard

Sharma S., Galanina N., Guo A., Lee J., Kadri S., Van Slambrouck C., Long B., Wang W., Ming M., Furtado L. V., Segal J. P., Stock W., Venkataraman G., Tang W., Lu P. and Wang Y. L. (20180322). Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. : Oncotarget.

MLA

Sharma Shruti, Galanina Natalie, Guo Ailin, Lee Jimmy, Kadri Sabah, Van Slambrouck Charles, Long Bradley, Wang Weige, Ming Mei, Furtado Larissa V, Segal Jeremy P, Stock Wendy, Venkataraman Girish, Tang Wei-Jen, Lu Pin and Wang Yue Lynn. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. : Oncotarget. 20180322.

  • Print
  • Cite
  • Add to your cart (remove)
  • Save record
    BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
  • More searches
    Search for this title in:
    Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Visit web site